Edition:
United Kingdom

Benitec Biopharma Ltd (BNTC.OQ)

BNTC.OQ on NASDAQ Stock Exchange Capital Market

4.02USD
6:43pm GMT
Change (% chg)

$0.41 (+11.36%)
Prev Close
$3.61
Open
$4.10
Day's High
$4.15
Day's Low
$3.82
Volume
41,342
Avg. Vol
11,221
52-wk High
$5.48
52-wk Low
$1.55

Chart for

About

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Benitec Biopharma ‍Says U.S. FDA Granted Orphan Drug Designation To BB-301​

* ‍U.S. FDA HAS GRANTED ORPHAN DRUG DESIGNATION TO BB-301 FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY(OPMD)​ Source text for Eikon: Further company coverage:

14 Jan 2018

BRIEF-Benitec Biopharma Posts Qtrly ‍Loss Of A$2.9 mln

* QTRLY ‍LOSS OF A$2.9 MILLION VERSUS PROFIT OF A$0.8 MILLION​ Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-Benitec Biopharma provides update On Opmd Orphan Disease program

* BENITEC BIOPHARMA PROVIDES UPDATE ON OPMD ORPHAN DISEASE PROGRAM

27 Nov 2017

BRIEF-Benitec Biopharma says working with regulators to advance BB-301 into the clinic as quickly as possible

* Benitec Biopharma says its BB-301, represents clinical candidate that it intends to advance into human clinical trials in the second half of 2018‍​

08 Aug 2017

Earnings vs. Estimates